Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk, first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen.

Haematologica

Published: January 2025

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694122	PMC
http://dx.doi.org/10.3324/haematol.2024.285837	DOI Listing

Publication Analysis

blinatumomab associated

associated better

better post-transplant

post-transplant outcome

outcome chemotherapy

chemotherapy children

children high-risk

high-risk first-relapse

first-relapse b-cell

b-cell acute

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!